Literature DB >> 3567292

Carryover and the two-period crossover clinical trial.

A R Willan, J L Pater.   

Abstract

The use of the two-period crossover trial for comparing two noncurative treatments in patients with a chronic disease is appealing since it eliminates the between-subject variability. However, the possibility of the existence of carryover effect leads many authors to advise that a parallel design be used whenever carryover is suspected. We examine this advice and quantify the degree of carryover required to make the parallel design preferable in terms of the power of the test of treatment effect and precision of the estimate of treatment difference. We conclude that in many situations this amount of carryover is substantial and unlikely to exist.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3567292

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  7 in total

Review 1.  Crossover studies are a better format for comparing equivalent treatments than parallel-group studies.

Authors:  T J Cleophas; E M de Vogel
Journal:  Pharm World Sci       Date:  1998-06

Review 2.  Which treatment is better? Ascertaining patient preferences with crossover randomized controlled trials.

Authors:  David Hui; Donna S Zhukovsky; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2014-12-30       Impact factor: 3.612

3.  A note on point estimation and interval estimation of the relative treatment effect under a simple crossover design.

Authors:  Chii-Dean Lin; Kung-Jong Lui
Journal:  Pharm Stat       Date:  2021-11-09       Impact factor: 1.234

4.  Injuries on the Youth Soccer (Football) Field: Do Additional Referees Reduce Risk? Randomized Crossover Trial.

Authors:  David C Schwebel; D Leann Long; Leslie A McClure
Journal:  J Pediatr Psychol       Date:  2020-08-01

5.  Milk protein-based formulas containing different oils affect fatty acids balance in term infants: A randomized blinded crossover clinical trial.

Authors:  Carolina Oliveira de Souza; Maria Efigênia Q Leite; John Lasekan; Geraldine Baggs; Lorena Silva Pinho; Janice Izabel Druzian; Tereza Cristina M Ribeiro; Ângela P Mattos; José A Menezes-Filho; Hugo Costa-Ribeiro
Journal:  Lipids Health Dis       Date:  2017-04-14       Impact factor: 3.876

6.  Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol.

Authors:  Jordana B Cohen; Thomas C Hanff; Vicente Corrales-Medina; Preethi William; Nicolas Renna; Nelson R Rosado-Santander; Juan E Rodriguez-Mori; Jonas Spaak; Jaime Andrade-Villanueva; Tara I Chang; Alejandro Barbagelata; Carlos E Alfonso; Eduardo Bernales-Salas; Johanna Coacalla; Carlos Augusto Castro-Callirgos; Karen E Tupayachi-Venero; Carola Medina; Renzo Valdivia; Mirko Villavicencio; Charles R Vasquez; Michael O Harhay; Jesse Chittams; Tiffany Sharkoski; James Brian Byrd; Daniel L Edmonston; Nancy Sweitzer; Julio A Chirinos
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-16       Impact factor: 3.738

7.  Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial.

Authors:  Jeffrey M Statland; Brian N Bundy; Yunxia Wang; Dipa Raja Rayan; Jaya R Trivedi; Valeria A Sansone; Mohammad K Salajegheh; Shannon L Venance; Emma Ciafaloni; Emma Matthews; Giovanni Meola; Laura Herbelin; Robert C Griggs; Richard J Barohn; Michael G Hanna
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.